TB Research

Improved treatment completion with shorter treatment regimens for latent tuberculous infection

Macaraig MM, Jalees M, Lam C, Burzynski J

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2018-11

Abstract

Setting Four New York City (NYC) Health Department tuberculosis (TB) clinics. Objective To assess the effectiveness of preferentially offering two shorter treatment regimens-4 months of daily rifampin (4R) and 3 months of once-weekly isoniazid and rifapentine (3HP)-as an alternative to 9 months of daily isoniazid (9H) for the treatment of latent tuberculous infection (LTBI). Design Retrospective analysis of patients treated for LTBI from January to June 2015. Poisson regression with robust standard error was used to examine the factors associated with treatment completion. Results Of the patients on 9H, 49% (27/55) completed treatment compared with 70% (187/269) of patients on 4R ( P = 0.003) and 79% (99/125) of patients on 3HP ( P Conclusions Most patients were placed on shorter regimens for LTBI treatment, and higher treatment completion was observed. Encouraging community providers to use shorter regimens for LTBI treatment would reduce the TB disease burden in NYC.

MeSH terms

  • Humans
  • Isoniazid
  • Rifampin
  • Antitubercular Agents
  • Treatment Outcome
  • Directly Observed Therapy
  • Drug Therapy, Combination
  • Drug Administration Schedule
  • Risk Factors
  • Retrospective Studies
  • Time Factors
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Middle Aged
  • Child
  • Child, Preschool
  • Infant
  • Infant, Newborn
  • New York City
  • Female
  • Male
  • Medication Adherence
  • Young Adult
  • Latent Tuberculosis
  • Drug-Related Side Effects and Adverse Reactions